The world’s largest vaccine maker, Serum Institute of India (SII), which is working in collaboration with the Indian Council for Medical Research (ICMR) to find a vaccine for Covid-19, announced Wednesday that it has completed registration of the Phase 3 clinical trials for your Covishield candidate.
IBS and ICMR are currently conducting Phase 2/3 clinical trials of Covishield at 15 different centers across the country, the Pune-based pharmacist said in a statement. Up to 1,600 participants signed up on October 31, he added.
Follow the latest updates on coronavirus here
“The strategic alliance between the SII and the ICMR will advance India’s role in the global race to develop Covid-19 vaccines,” the drug maker said in a statement.
The IBS said the Oxford vaccine trials have shown promising results, which “so far give confidence that Covishield could be a realistic solution to the deadly pandemic.”
Among the vaccines being developed in India, Covishield is in the most advanced stage of human testing. Based on the results of the phase 2/3 trial, SII with the help of ICMR will seek early availability of this product for India, the company said, adding that it has already manufactured 40 million doses under the manufacturing license. and storage at risk of DCGI.
In addition to Covishield, developed in the Pune lab with a master seed from the University of Oxford / AstraZeneca, ICMR and SII have also collaborated for the clinical development of Covovax developed by US-based Novavax.
Adar Poonawalla, Executive Director of the Serum Institute of India, said the pandemic has presented an opportunity to foster structural reforms in building a strong public health infrastructure, adding: “ICMR has played a very important role in advancing and strengthening of India’s fight against Covid-19. The collaboration will further help us put India at the forefront of developing an effective and immunogenic vaccine. “
ICMR CEO Dr. Balram Bhargava noted the role India plays in global vaccine development and manufacturing. “Driven by the latest technology and well-equipped facilities, SII has continually demonstrated its prowess in research and manufacturing. The association is our contribution to provide our experience and support to strengthen our fight against the global pandemic ”, he added.
.
